Product finder
Anti-LGR5 pure, human – Western blotting
Optimized for the detection of LGR5 by Western blot analysis.
June 16, 2014
Human FGF-2 IS
Engineered for increased thermostability, provides a constant and stable signal for maintenance of undifferentiated ES/iPS cells.
June 16, 2014
MACSPlex Cytokine 10 Kit, mouse
Determine concentrations of multiple soluble cytokines in a single sample by flow cytometry.
June 16, 2014
StemMACS™ iPS-Brew XF, human
A xeno-free media formulation for human ES or iPS cell culture. Make your choice for seamless translation today.
May 9, 2014
Miltenyi Biotec acquires gene therapy assets from Lentigen corporation
Miltenyi Biotec announced today that it has acquired the lentiviral vector manufacturing business and related assets from US company Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications.
August 14, 2014
CiteAb highlights Miltenyi Biotec
The world's most popular antibody search engine CiteAb is featuring Miltenyi Biotec on its start page highlighting company facts and our brand new REAfinity™ Antibodies. This prominent placement helps to position Miltenyi Biotec as a high-quality flow antibody provider. A valuable characteristic of this search engine is that the results are ranked by citations, which is a significant quality criterion to trigger antibody purchases.
June 23, 2014
FDA Approval of CliniMACS® CD34 Reagent System
Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) in first complete remission undergoing allogeneic stem cell transplantation (SCT) from a matched related donor.
January 24, 2014

Customer login


Forgot password?
Register for account

0 Shopping cart


Miltenyi Biotec Inc.
Phone: +1 800 FOR MACS
Fax:+1 530 745 2806
Contact overview

Product finder

Antibody panel builder


Change country

Please select your country to continue